A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor

This study is an open-label, dose-escalation, multicenter Phase I/II study conducted in patients with advanced solid tumors. The target population for this study consists of patients with advanced solid tumors who have failed or are intolerant to standard treatments. The study is divided into two parts: the dose-escalation phase and the dose-expansion phase.

NCT Number	NCT07327294
Lead Sponsor	Evopoint Biosciences Inc.
Conditions	Advanced Solid Tumors
Enrollment	150 participants
Start Date	2026-01-31
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-08